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Abstract
Background: There is increasing evidence that phloroglucinol, a compound from Ecklonia cava, induces the apoptosis of
cancer cells, eventually suppressing tumor angiogenesis.
Methodology/Principal Findings: This is the first report on phloroglucinol’s ability to potentially inhibit the functional
bioactivities of endothelial progenitor cells (EPCs) and thereby attenuate tumor growth and angiogenesis in the Lewis lung
carcinoma (LLC)-tumor-bearing mouse model. Although Phloroglucinol did not affect their cell toxicity, it specifically
inhibited vascular endothelial growth factor (VEGF) dependent migration and capillary-like tube formation of EPCs. Our
matrigel plug assay clearly indicated that orally injected phloroglucinol effectively disrupts VEGF-induced neovessel
formation. Moreover, we demonstrated that when phloroglucinol is orally administered, it significantly inhibits tumor
growth and angiogenesis as well as CD45
2/CD34
+ progenitor mobilization into peripheral blood in vivo in the LLC-tumor-
bearing mouse model.
Conclusions/Significance: These results suggest a novel role for phloroglucinol: Phloroglucinol might be a modulator of
circulating EPC bioactivities, eventually suppressing tumorigenesis. Therefore, phloroglucinol might be a candidate
compound for biosafe drugs that target tumor angiogenesis.
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Introduction
Phloroglucinol is a compound from Ecklonia cava, a species of
brown alga. Recently, this biomolecule has attracted attention for
drug synthesis because of its anti-inflammatory [1], anti-microbial,
anti-allergic, and antioxidant activities [2,3] and human immu-
nodeficiency virus (HIV)-1 reverse transcriptase and protease
inhibitor activities [4]. However, little is known about its effect on
progenitor cell-mediated tumor angiogenesis.
Tumor angiogenesis is a pivotal step in tumor growth because
blood vessels generated by this pathophysiological process supply
cancer cells with nutrients and oxygen, which are indispensable for
the proliferation and survival of these cells. Emerging data shows
that adequate inhibition of tumor angiogenesis can attenuate
tumor growth [5]. Recently, the screening of natural products for
anti-cancer properties has come into focus because these
biomolecules cause few side-effects and have strong specific tumor
cell targeting effects [6,7,8].
During tumor angiogenesis as well as vascular injury, circulating
progenitor cells are dynamically mobilized from the bone marrow
into the circulating blood, leading to vasculature remodeling
[9,10,11,12,13]. Neovessel formation during tumor progression
seems to be closely related to endothelial cells (EC)-mediated
angiogenesis. Bone marrow (BM)-derived circulating progenitors
including mesenchymal stem cells (MSCs), endothelial progenitor
cells (EPCs) and hematopoietic precursor cells (HPCs) also
contribute to this process [14,15,16]. However, therapeutic target
molecules that effectively inhibit tumor angiogenesis by modulat-
ing stem/progenitor cells remain to be identified.
In the present study, we hypothesize that phloroglucinol is a
good candidate anti-cancer biomolecule that modulates tumor
growth during tumor progression by inhibiting the bioactivities of
EPCs. Indeed, we demonstrated phloroglucinol’s inhibitory effect
on the cell migration, and capillary-like tube formation of EPCs
using an in vitro functional assay. Importantly, orally treatment
with phloroglucinol effectively disrupted vascular endothelial
growth factor (VEGF)-induced de novo vessel formation in an in
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33618vivo murine matrigel plug assay. In the in vivo Lewis lung carcinoma
(LLC)-tumor-bearing mice model, we showed that oral adminis-
tration of phloroglucinol significantly inhibited tumor growth and
angiogenesis as well as the mobilization of circulating EPCs,
CD45
2/CD34
+ progenitor cells. This report highlights a novel
role for phloroglucinol as a modulator of EPC bioactivities and
suggest that it might be a potential cancer prevention drug.
Results
Characterization of EPCs from human umbilical cord
blood (HUCB)
EPCs have been isolated from HUCB mononuclear cells
(MNCs). Fluorescent staining was used to detect double positive
cells binding of fluorescein isothiocyanate (FITC)-labeled Ulex
europaeus agglutinin-1 (UEA-1) lectin and dioctadecyl-3,3,39,39-
tetramethylindo carbocyanine (Dil)-labeled acetylated low density
lipoprotein (data not shown). Immunophenotyping further re-
vealed that ex vivo expanded EPCs expressed endothelial cells
lineage surface antigens, CD31, VEGFR-2 (KDR), von Will-
ebrand factor (vWF), eNOS, p-eNOS and p-Akt (Fig. 1B).
Effect of phloroglucinol on cell toxicity of EPCs
In order to investigate cytotoxity of phloroglucinol in EPCs, cell
viability assay was performend. As shown in Fig. 1C, Phloroglu-
cinol did not reduce cell viability in EPCs at doses below 100 mM
for 24 h. Therefore, concentrations of phloroglucinol ranging
from 2 to 100 mM were selected for study on bioactivities of EPCs
and tumor angiogenesis.
Phloroglucinol inhibits the VEGF-induced migration of
EPCs
Considering that BM mobilization kinetics of EPCs into
peripheral blood (PB) is generally initiated by VEGF signaling,
phloroglucinol may modulate the VEGF-induced migratory
capability of EPCs. To test this idea, we next examined the effect
of phloroglucinol on the migratory capability of EPCs using the
wound healing assay. As shown in Figure 2A and 2B, induction of
VEGF significantly repaired the wounded monolayer of EPCs. In
contrast, phloroglucinol significantly reduced the VEGF-induced
wounded area in a dose-dependent manner.
Phloroglucinol inhibits the tube-forming capacity of EPCs
We further identified the effect of phloroglucinol on the de novo
capillary-like tubular formation of circulating progenitor cells
(Fig. 3A). Treatment with phloroglucinol resulted in significant
reduction in the number of branches and length of EPC tubes in a
dose-dependent manner (Fig. 3B and 3C).
Phloroglucinol suppresses tumor growth and tumor
angiogenesis
In order to explore whether daily oral administration of
phloroglucinol can suppress tumor growth and tumor-induced
angiogenesis, we generated in vivo LLC tumor-bearing mice. To do
this, we injected LLC tumor cells into male C57BL/6 mice,
following which they were orally administered 0.94 mg/kg
phloroglucinol (experimental group) or DMSO solvent (control
group) daily for 24 days (Fig. 4A). At the time of death, all the mice
treated with the vehicle only had a large tumor volume reaching
2.1060.309 cm
3. A significant decrease in swelled tumor mass
(1.06260.341 cm
3) was observed when LLC cells (5610
4) were
injected into a mouse flank together with phloroglucinol (Fig. 4B).
To further determine the direct effects of phloroglucinol on tumor-
induced angiogenesis, we analyzed the capillary density of the
peritumoral region of each group by staining sections with CD31
antibodies. As shown in Figure 4C and 4D, treatment with
phloroglucinol led to a significant reduction in the number of
CD31
+ capillary microvessels in the peritumoral region, suggesting
that phloroglucinol might suppress tumor-induced angiogenesis in
vivo. In order to investigate the direct role of phloroglucinol during
EPC –mediated tumor angiogenesis, we analyzed the number of
incorporated EPC in tumor vessel following orally administration
of phloroglucinol. As shown in Figure S1, phloroglucinol
significantly inhibited EPC incorporation into tumor-mediated
vessels when isolated labelled EPCs applied into tail vein of tumor
bearing mice, suggesting that phloroglucinol effectively modulated
the contribution of EPC during tumor angiogenesis, partly
regulating migratory capabilities of EPC.
Effect of phloroglucinol on mobilization of circulating
EPCs, CD45
NEGCD34
POScells
Since orally administered phloroglucinol in tumor-bearing mice
exerts a significant inhibitory effect on the mobilization of
circulating EPCs, we performed additional experiments to
determine the effect of phloroglucinol treatment on the mobiliza-
tion of EPCs from the bone marrow (BM) niche into circulating
blood. Following subcutaneous transplantation (5610
6 cells) of
LLC into the thighs of C57BL/6 mice, they were orally
administrated 0.94 mg/kg phloroglucinol for 5 days (Fig. 5A).
As shown in Figure 5B, the number of CD45
NEGCD34
POS cells,
i.e., circulating EPCs, significantly increased compared to in
normal mice. Importantly, oral administration of phloroglucinol
for 5 days resulted in a significant reduction in the number of
CD45
NEGCD34
POS EPCs circulating in PB.
Phloroglucinol inhibits VEGF-induced in vivo
angiogenesis
In order to investigate the reason for phloroglucinol’s anti-
angiogenic activity in the in vivo angiogenesis model, we performed
a matrigel plug assay (Fig. 6A). As shown in Figure 6B, the group
with VEGF-loaded plugs yielded a red image, indicating an
abundance of red blood cells in the newly formed vessels, while
plugs with matrigel alone or with 0.94 mg/kg and 9.4 mg/kg
phloroglucinol yielded light yellow images, indicating compara-
tively less blood vessel formation. These results suggest that
phloroglucinol significantly reduces VEGF-dependent neovessel
formation. To further examine the effect of phloroglucinol on
capillary density, we performed immunohistochemical analysis by
staining of CD31+ microvessels (Fig. 7A). As shown in Figure 7B,
there was a significant decrease in the density of microvessels in the
group with plugs with phloroglucinol plus VEGF as compared to
the group with plugs with VEGF only.
Discussion
Tumor-mediated neovascularization refers to the formation of
new blood vessels from pre-existing vessels via the migration and
proliferation of endothelial cells. This process requires multiple
pathophysiological steps during the process of blood vessel
formation, and it eventually contributes to tumor growth and
angiogenesis [17,18]. BM-derived EPCs are reported to play a
significant role in tumor angiogenesis [19,20]. Emerging evidence
indicates impairments in the homing activities of BM-derived
endothelial and hematopoietic precursor cells significantly blocks
tumor angiogenesis and growth by decreasing the growth of early
tumors. Blocking occurs because of interference in the angiogenic
switch, which promotes tumor neovessel formation during tumor
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bone marrow microenvironment to the peripheral blood may be
an attractive target for anti-cancer treatments [9,21,22,23]. This
hypothesis explains why we were interested in understanding if the
anti-tumor activities of phloroglucinol involve in inhibiting the
bioactivities of EPCs and if these activities eventually suppress
tumor growth and angiogenesis in the LLC-tumor-bearing mouse
model.
Phloroglucinol compounds, both synthetic as well as natural,
have a wide range of industrial applications because of their
various biological activities such as anti-inflammatory, anti-
microbial, anticancer, enzyme inhibitory, anti-allergic, anti-
oxidant, and neurodegenerative activities [1,2,3,24]. In general,
hyperforin formulations, which are phloroglucinol derivatives,
have been used to treat various types of cancer and precancerous
tumors because they exert anti-proliferative bioactivities by
activating the intrinsic apoptosis pathways of a panel of tumor
cell lines, including carcinoma and leukemia cells as well as
endothelial cells. Further, these formulations can be used to treat
angioproliferative retinopathy and skin diseases, in which
pathological angiogenesis occurs [25,26,27]. This study presents
novel findings that oral administration of phloroglucinol signifi-
cantly reduces de novo neovessel formation in LLC tumor tissue by
affecting EPCs bioactivities including their migratory capability,
Figure 1. Effect of phloroglucinol derivatives isolated from Ecklonia cava on cell toxicity of EPCs. (A) Chemical structure of phloroglucinol:
a class of natural products containing 1,3,5-trihydroxybenzene as the basic moiety. (B) Immunophenotyping of cell monolayers derived from HUCB
EPCs by fluorescence microscope. A representative image is shown for HUCB EPCs. Immunophenotyping revealed that EPCs expressed endothelial
cells lineage antigens including CD31, VEGFR-2 (KDR), VWF, eNOS, p-eNOS and p-Akt. (C) After treatment of phloroglucinol in EPCs, cell viability was
examined using an MTT assay.
doi:10.1371/journal.pone.0033618.g001
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EPCs into the peripheral circulation. Among the proposed pivotal
mediators of tumor-mediated neovascularization, VEGF signaling
has been identified as the central signaling axis regulating
proliferative activities, migration, and homing/incorporation of
EPCs into sites of ischemic tissue [28,29]. Thus, a wide range of
preclinical strategies for the VEGF pathway has been shown to
hinder tumor growth and angiogenesis [29,30]. Increasing
evidence shows that a VEGF-neutralizing antibody (bevacizumab)
and VEGF receptor tyrosine kinase inhibitor (RTKIs), including
sorafenib and sunitinib, are clinically approved anticancer
treatments that target the VEGF/VEGF receptor axis
[31,32,33]. Importantly, as shown in Figure S2, phloroglucinol
more effectively inhibited tube forming capacity and migratotory
capacity in low concentration as compared to those of bevacizu-
mab. Based on the present findings, we concluded that
phloroglucinol showed more superiority of phloroglucinol over
well established, clinically proven antiangiogenic drug- bevacizu-
mab, partly affecting in vitro bioactivities of EPCs in intracellular
VEGF-mediate signal cascades, although bevacizumab can only
modulate surface-mediated VEGF signaling.
This is the first report that phloroglucinol inhibits multiple
VEGF-dependent EPC bioactivities, including the VEGF-depen-
dent tube-forming capability and VEGF-dependent migratory
capacity of EPCs in vitro. Further, this compound effectively
abrogates VEGF-dependent neovessel formation in vivo, leading to
delayed tumor progression and angiogenesis, partly through the
modulation of EPCs in vivo.
Figure 2. Effect of various concentrations of phloroglucinol on the migratory activity of EPCs in a wound healing assay. (A) Ex vivo
cultured outgrowth ECs were subjected to a wound healing migration assay. Bar: 500 mm. EPCs were wounded and treated with 100 ng/ml of VEGF
with or without 20 ı `M or 100 ı `M of phloroglucinol or a vehicle. (B) Bar graph represents the number of migrated cells. Fields were chosen randomly
from various section levels to ensure objective sampling. In response to phloroglucinol, the VEGF-induced migratory activity of EPCs was significantly
decreased.
doi:10.1371/journal.pone.0033618.g002
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cascade underlying the phloroglucinol-dependent inhibition of
tumor-mediated EPC mobilization during tumor angiogenesis can
provide clues regarding cancer spread and metastatic growth since
blockage of the process by phloroglucinol may be a significant
target for therapeutic treatments [34,35]. Interestingly, we recently
observed that the effect of phloroglucinol on EPC mobilization
seems to involve in altered VEGF dependent actin reorganization,
not decreased VEGF levels in blood by phloroglucinol, suggesting
that phloroglucinol might affect the bioactivities of EPCs including
cytoskeletal changes (Figure S3). In particular, tumor cell-
associated proteinases such as matrix metalloproteinases MMP2
and MMP9 [36,37,38] might play a role in the decline of
mechanical barriers represented by extracellular matrices and may
be closely related to the incorporation process and importance of
EPCs during tumor angiogenesis.
Figure 3. Effect of phloroglucinol on tubule-like structure formation of EPCs. (A) Representative tubular network structure of VEGF-
stimulated outgrowths of ECs treated with or without phloroglucinol. Bevacizumab was used as a positive control. Bar: 500 mm. (B, C) Tube branches
and total tube length were quantified using MacBiophotonics Images J software. Bar graph represents the number of intact loops in the capillary
networks. Graph represents the length of tubes in the capillary networks (*P,0.05, **P,0.01).
doi:10.1371/journal.pone.0033618.g003
Inhibition of Tumor Angiogenesis by Phloroglucinol
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33618Taken together, our data provide some evidence that
phloroglucinol from edible and medicinal plants might be a
potential drug for cancer prevention and/or chemotherapies.
Materials and Methods
Ethical statement
After obtaining informed consent, human umbilical cord blood
was collected from healthy volunteers according to a protocol
approved by the Ethics Review Board of the Hospital of the Pusan
National University of YangSan, Korea. We have the list of the
volunteers that university hospital can share. The Institutional
Animal Care and Use Committee of the CHA University, Seoul,
Korea approved all surgical interventions and post-operative animal
care. The consent was written and approved. The approved protocol
number is IACUC090017. Therefore, the Ethics Review Board
approved this research including both the human and animal studies.
Figure 4. Effect of phloroglucinol on tumor growth and tumor angiogenesis in LLC tumor-bearing mice. (A) Male C57BL/6 mice were
injected subcutaneously with 5610
4 LLC cells. LLC tumor-bearing mice were treated with DMSO solvent control and phloroglucinol at 0.94 mg/kg
daily for 24 days after initiation of therapy. (B) Tumor growth was measured with calipers every 3 or 4 days using the formula
V=height6length6depth (cm
3). All data are represented as the mean tumor volume 6 SE for the 7 animals in each group.. (C) Representative
photomicrographs of CD31 capillaries in tumor sections stained with rat anti-mouse CD31 (green fluorescence), a typical endothelial marker. Nuclei
were counterstained with DAPI (blue). Sections were photographed at 6100 magnification using an fluorescent microscope. Bar: 500 mm, (D)
Quantification of the density of CD31
+ capillary neovessels. The number of CD31-stained capillaries was counted using the Image J program. Fields
were chosen randomly from various section levels to ensure objective sampling (*P,0.05).
doi:10.1371/journal.pone.0033618.g004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33618Figure 5. Effect of phloroglucinol on EPC mobilization in LLC tumor-bearing mice. (A) Schematic experimental schedule of in vivo EPC
mobilization kinetics. After subcutaneous injection with 5610
6 LLC, the mice were orally administered DMSO vehicle (control) or 0.94 mg/kg
phloroglucinol daily for 5 days after the initiation of therapy. Circulating MNCs were harvested at day 5 by Ficol-gradient centrifugation. (B) A
Inhibition of Tumor Angiogenesis by Phloroglucinol
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33618Reagents
Phloroglucinol was purchased from Sigma-Aldrich (P1178). A
solution of phloroglucinol was dissolved in dimethyl sulfoxide
(DMSO, Amresco). The chemical structure of phloroglucinol is
shown in Figure 1A.
Cell culture of circulating EPCs and LLC cells
EPCs were cultured according to a previously described
technique [39]. The Ethics Review Board of the Hospital of the
Pusan National University of YangSan, Korea, approved the
protocols, and the experimental study was conducted in
accordance with the Declaration of Helsinki. In brief, mononu-
clear cells (MNCs) were isolated from human umbilical cord blood
(HUCB). HUCB samples (approximately 60 ml each) were
collected from fresh placentas with attached umbilical cords,
using density gradient centrifugation with Ficol separating solution
(Amersham). Freshly isolated MNCs were cultivated in 100 mm
dishes coated with 1% gelatin (Sigma). The cultivation medium
subsequent gate was used to select the total CD45
NEG cell population. Corresponding flow cytometric analysis was used to detect CD34
POS cells in the
gated CD45
NEG cell population. The EPC population was represented as CD45
NEG/CD34
POS cells. (C) Statistical difference between phloroglucinol after
oral administration of both phloroglucinol and vehicle in LLC-tumor bearing mice. Bar graph represents marked differences in EPC frequency at day 5
after daily injection of phloroglucinol or vehicle (*P,0.05).
doi:10.1371/journal.pone.0033618.g005
Figure 6. Phloroglucinol attenuated VEGF-dependent angiogenesis a in matrigel plugs assay. (A) Experimental protocols used in the
VEGF-dependent matrigel plug assay. (B) Representative matrigel plug of each group at 13 days after injection. C57BL/6 mice (n=5 per group) were
subcutaneously injected with growth factor-reduce matrigel alone (none) or a combination of VEGF (300 ng/ml) and phloroglucinol (0.94 mg/kg and
9.4 mg/kg). VEGF loaded plugs from mice exhibited red color indicating abundant red blood cells.
doi:10.1371/journal.pone.0033618.g006
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supplemented with 5% fetal bovine serum (FBS), human basic
fibroblast growth factor (bFGF), human vascular endothelial
growth factor (hVEGF), human insulin-like growth factor-1
(hIGF-1), human epidermal growth factor (hEGF), ascorbic acid,
and GA-1000 (complete EGM-2 medium). After 4 days, non-
adherent cells were removed, and the tightly attached fraction of
cells were re-plated and cultured for another 3 days. Cultivation
was continued by refreshing the EGM-2 medium until spindle-
shaped colonies were formed after 14–21 days. Medium was
changed daily for 7 days and then every other day until the first
passage. Endothelial characteristics of the attached spindle-shaped
EPCs were examined. Immunohistochemistry revealed that our
late EPCs (ex vivo cultured outgrowth ECs) express several
endothelial lineage markers using various antibodies against
CD31, VEGF receptor-2 (KDR/Flk-1), von Willebrand factor
(vWF), eNOS, p-eNOS and p-Akt. . Lewis lung carcinoma (LLC)
cells were obtained from College of Pharmacy, Research Institute
of Pharmaceutical Sciences, Kyungpook National University. The
LLC cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM, WelGENE) supplemented with 10% FBS and
1% penicillin/streptomycin (Gibco, Eggenstein, Germany) [40].
Figure 7. Phloroglucinol decreased the number of CD31(+) vessels a in matrigel plugs assay. (A) Representative photomicrographs of
CD31-stained matrigel sections obtained from mice treated with the vehicle. After 13 days, the mice were sacrificed, and the matrigel plugs were
removed. The histological sections were fixed with 4% paraformaldehyde and embedded in paraffin. Infiltrating endothelial cells in plugs stained
during an immunohistochemistry assay of anti-CD31 antibody. Bar: 500 mm. (B) Quantitative assessment of CD31-positive capillaries (*P,0.05,
**P,0.01).
doi:10.1371/journal.pone.0033618.g007
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The cytotoxic effects of the isolated compounds on cultured cells
were measured using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay. In brief, ex vivo expanded
EPCs (1610
4 cells/well) were plated onto gelatin-coated, 96-well
plates containing complete EGM-2 medium. After 24 h, the cells
were serum starved in EBM-2 medium supplemented with 0.5%
FBS for 12 h. They were then incubated with various concentra-
tions of phloroglucinol in complete EGM-2 medium for 24 h.
These were then incubated with 20 m, MTT solution (5 mg/ml,
Amresco) for 4 h. Finally, 200 m, DMSO was added to solubilize
the formed formazan, and the amount of formazan formed was
determined by measuring the absorbance at 560 nm using a
microplate reader. Viability of cells was quantified as a percentage
compared to the control, and dose response curves were
developed.
Migration assay
Ex vivo expanded EPCs were cultured in 24-well plates at
1.5610
5 cells/well as confluent monolayers. The cells were
incubated in EGM-2 medium for 24 h. Cells were starved in
EBM-2 medium containing 1% FBS for 6 h and wounded. The
wounded monolayer was then washed to remove cell debris,
incubated for 14 h in 0.1% FBS in EBM-2 media containing
various concentrations of phloroglucinol or bevacizumab and
VEGF (100 ng/ml, Biobud). The area of the wound was recorded
at the indicated time points using a light microscope. Migrated
cells were analyzed under a light microscope.
Tube formation assay
Matrigel (BD Biosciences, Bedford, MA) was dissolved at 4uC
overnight, and 96-well plates were prepared with 55 m, matrigel
in each well after coating and incubating at 37uC for 30 min.
EPCs (2610
4) in 100 m, complete EGM-2 media were added with
various concentrations of phloroglucinol or bevacizumab. After
6,24 h of incubation at 37uC, EPCs’ tube formation was assessed
with a photomicroscope, following which each well was photo-
graphed at 640 magnification under a light microscope. Tube
branches and total tube length were calculated using MacBiopho-
tonics Image J software.
In vivo tumor growth
Male C57BL/6 mice were injected subcutaneously with 5610
4
LLC cells in DMEM. Drug treatment was initiated the day after
tumor injection. LLC tumor-bearing mice (7 per group) were
treated for 24 days with 150 m, of 0.94 mg/kg phloroglucinol or
the solvent (10% DMSO). Tumor growth was measured with
calipers every 3 or 4 days using the following formula:
V=height6length6depth (cm
3) [41]. We designed the in vivo
tumor model of phloroglucinol to identify the possibilities as a
tumor preventing drug, as phloroglucinol, a compound from
Ecklonia cava, a species of brown alga and can be edible, biosafe
natural bioproducts and can be used as a tumor preventing bio-
drug. Therefore, we orally administrated phloroglucinol one day
after tumor injection to evaluate the effect of phloroglucinol before
initiating tumor.
Contribution of EPCs during phloroglucinol-mediated
tumor angiogenesis
To determine incorporation ratio of EPCs into tumor vessel by
orally administrated phloroglucinol, the Dil-Ac-LDL-labeling-
EPCs (1610
6 cells) were transplanted into tail vein of LLC-
tumor-bearing C57BL/6 mouse (5 per group). Tumor tissue
samples collected from the experimental animals were fixed 4%
paraformaldehyde, rinsed in PBS, transferred to 30% sucrose in
PBS at 4uC, and frozen in OCT compound. Frozen tissue sections
were treated using goat anti-mouse CD31 antibody overnight at
4uC, followed by staining with FITC conjugated anti-goat
antibody to identify capillaries in tumor.
In vivo mobilization of circulating EPCs,
CD45
NEGCD34
POScells
Male C57BL/6 mice were injected subcutaneously with 5610
6
LLC cells in DMEM. Phloroglucinol treatment was initiated the
day after tumor injection. LLC tumor-bearing mice (5 per group)
were treated for 5 days with 0.94 mg/kg phloroglucinol. Control
mice received equal amounts of 10% DMSO. Thereafter, mouse
circulating EPCs were determined with flow cytometry using the
following labels: CD45 (to exclude hematopoietic cell) (BD
Pharmingen), hematopoietic/endothelial progenitor cell marker
CD34 (BD Pharmingen) antibodies.
Enzyme-Linked Immunosorbent Assay (ELISA)
Seven-week-old C57BL/6 mice were received subcutaneous
injection with LLC cells (1610
6 cells). At starting day after tumor
inoculation, they were orally administered 0.94 mg/kg phloroglu-
cinol or DMSO solvent (control group) into LLC tumor bearing
mice daily for 7 days. Using blood samples, ELISA was performed
with a mouse specific VEGF ELISA kit (Quantikine M, R&D
system, Minneapolis, Minn), as indicated in the manufacturer’s
protocol.
Actin reorganization in response to VEGF
EPCs were seeded sparsely onto microscope glass coverslips
placed within 24 well culture plates and allowed to grow for 1 day
on change of the EGM-2 medium. Cells were starved in EBM-2
medium containing 0.1% FBS for 12 h. Incubated for 3 h in
EBM-2 media containing various concentrations of phloroglucinol
and VEGF (100 ng/ml, Biobud). Cells were fixed in 4%
paraformaldehyde in PBS at room temperature for 20 minutes.
Rhodamine-conjugated phalloidin was applied at room temper-
ature for 60 minutes. After washing the coverslips in PBS, they
were mounted onto object glasses using faramount mounting
medium (Dako) and analyzed using confocal microscope (Olym-
pus).
Flow cytometry analysis
Mouse circulating EPCs were determined with flow cytometry
using the following labels: CD45 (to exclude hematopoietic cell)
(BD Pharmingen), hematopoietic/endothelial progenitor cell
marker CD34 (BD Pharmingen) antibodies. Following red cell
lysis, circulating EPCs were enumerated using flow cytometry
(Becton Dickinson, Franklin Lakes, NJ), using gates to exclude
dead cells, debris, and platelets. The percentage of stained cells
was finally determined after comparing samples with matched
isotype controls.
Immunohistochemistry of CD31
+ micro vessels
Vasculogenesis in the tumor tissue was determined by
immunohistochemistry staining of CD31, a marker of endothelial
cells. The immunohistochemical reactions were carried out on 5-
mm-thick paraffin 4% paraformaldehyde-fixed-embedded sections
from the phloroglucinol or the solvent treatment group, and
paraffin sections of each tumor were stained for CD31 using a rat
anti-mouse CD31 monoclonal antibody (BD Pharmingen).
Specific binding of the primary antibody was visualized using
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The fields were chosen randomly from various section levels to
ensure the objectivity of sampling.
In vivo matrigel plug assay
Growth factor-reduced matrigel (0.6 ml) containing 20 U of
heparin and no VEGF, 300 ng/ml mouse VEGF, mouse VEGF
plus 0.94 mg/kg and 9.4 mg/kg of phloroglucinol was injected
subcutaneously into 7-week-old male mice. After 13 days, plugs
were removed from the sacrificed mice. The matrigel plugs were
fixed with 4% paraformaldehyde and embedded with paraffin.
Next, 5-mm sections were stained in an immunohistochemistry
assay with anti-CD31 antibody in order to visualize the endothelial
cells. The fields were chosen randomly from various section levels
to ensure the objectivity of sampling.
Statistical analysis
Statistical comparison of 2 groups was performed using the
Student’s t-test. The results were analyzed using the Statview 5.0
software package (Abacus Concepts, Inc., CA). Scheffe ´’s test was
performed for multiple comparisons between each group after
ANOVA. All data, which were obtained from at least 3
independent experiments, are expressed as means 6 standard
deviations.
Supporting Information
Figure S1 The direct role of phloroglucinol during EPC–
mediated tumor angiogenesis. (A) Representative photomi-
crographs of incorporated EPC (red fluorescence, Ac-LDL-labeled
EPC) into CD31 (+) neovessel (green fluorescence). (B) Quantita-
tive assessment of incorporated EPCs following orally administra-
tion of phloroglucinol. The bar graph represents a marked
difference in the number of incorporated EPCs in phloroglucinol –
treated mice.
(TIF)
Figure S2 Direct comparision of in vitro ant-angiogenic
effects between phloroglucinol and Bevacizumab. (A)
Effect of phloroglucinol and Bevacizumab on tubule-like structure
formation of EPCs. Tube branches and total tube length were
quantified using MacBiophotonics Images J software. Bar graph
represents the number of intact loops in the capillary networks.
Graph represents the length of tubes in the capillary networks
(*P,0.05, **P,0.01). (B) Effect of phloroglucinol and Bevacizu-
mab on the migratory activity of EPCs. EPCs were wounded and
treated with 100 ı `M of VEGF with or without 20 ng/ml or
100 ng/ml of phloroglucinol or Bevacizumab. (*P,0.05,
**P,0.01). The bar graph represents a marked difference in the
migratory activity of EPCs between phloroglucinol and bevacizu-
mab.
(TIF)
Figure S3 VEGF levels in blood of phloroglucinol-
injected LLC tumor-bearing mice and cytoskeletal
change of phloroglucinol-treated EPCs. (A) VEGF levels
were assessed by enzyme-linked immunosorbent assay in blood
following orally administration of phloroglucinol in LLC tumor-
bearing mice. (B) ltered actin reorganization in response to VEGF
in phloroglucinol-treated EPCs. Rhodamine-conjugated phalloi-
din (red fluorescence) was applied at room temperature for
60 minutes and analyzed using confocal microscope. The
representative image represents a marked difference in VEGF
dependent actin reorganization in phloroglucinol-treated EPCs.
(TIF)
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